Targeting angiogenesis with monoclonal antibodies

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Bicknell, R ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTIBODY; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FIBRONECTIN ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG TARGETING; HEART FAILURE; HUMAN; HYPERTENSION; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; THROMBOEMBOLISM; TUMOR VASCULARIZATION;

EID: 33749586115     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl241     Document Type: Article

References (27)

1. Jain RK, Duda DG, Clark JW et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.
2. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974.
3. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004; 25; 581-611.
4. Claffey KP, Brown LF, del Aguila LF et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56: 172-181.
5. Zhang HT, Scott PA, Morbidelli L et al. The 121 amino acid isoform of vascular enoothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000; 83: 63-68.
6. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-444.
7. Ferrara N, Hillan KJ, Gerber HP et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
8. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
9. Bevacizumab (Avastin) for the treatment of solid tumors: NCI fact Sheet [http://cancer.gov/cancertopicsfactsheet/AvastinFactSheet].
10. Rosen LS. VEGF-targeted therapy: Therapeutic potential and recent advances. Oncologist 2005; 10 (6): 382-391.
11. Sandler AB, Clinical trials comparing carboplatin/paclitaxel with and without bevacizumab in patients with metastatic NSCLC. Lung Cancer Update 2005; 2: 6-10.
12. Goffin JR, Talavera JR. Overstated conclusions of a pooled analysis of bevacizumab in colon cancer. J Clin Oncol 2006; 24: 528-529; author reply 529-530.
13. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
14. Hellmann K. Recognition of tumor blood vessel normalization as a new antiangiogenic concept. Nat Med 2004; 10: 329; author reply 329-30.
15. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of precancerous lesions and invasive carcinomas of the colon. Br J Cancer 2001; 84: 1354-1362.
16. McDonald DM, Choyke PL. Imaging of angiogenesis: From microscope to clinic. Nat Med 2003; 9: 713-725.
17. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7: 987-989.
18. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
19. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
20. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
21. Izumi Y, Xu L, di Tomaso E et al. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416 (6878): 279-280.
22. Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
23. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-969.
24. Toi M, Atiqur Rahman M, Bando H et al. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005; 6: 158-166.
25. Nikitenko LL, Fox SB, Kehoe S et al. Adrenomedullin and tumour angiogenesis. Br J Cancer 2006; 94: 1-7.
26. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5 (6): 436-446.
27. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993; 90: 8996-9000.